Corxel Pharmaceuticals closed a $287 million Series D financing to advance CX‑11, an oral small‑molecule GLP‑1 receptor agonist, through U.S. and global phase II trials and to prepare for phase III. The financing will also support Corxel’s broader cardiometabolic pipeline and regulatory preparations for pivotal studies. The company, headquartered in New Jersey with operations in Shanghai, said the funds will accelerate clinical development and global trial planning. The round underscores investor interest in oral GLP‑1 modalities and signals continued capital availability for obesity and diabetes-focused biotech programs.